Pharmacoeconomic evaluation of using enzalutamide for treatment of patients with metastatic hormone-sensitive prostate cancer

Background . The addition of enzalutamide to standard androgen deprivation therapy (ADT) significantly increases overall survival and progression-free in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared ADT. Objective : evaluate the incremental cost/effectiveness ratio (ICER) use mHSPC ICER as first-line for castration-resistant (mCRPC) from Russian healthcare system perspective assess contribution into reduction mortality Federation on horizon until 2024. Materials methods. Standard ADT regimens were used a comparator it is most common treatment Russia. We proposed Markov model progression + (hereinafter enzalutamide) or 1st generation antiandrogen ADT) based ENZAMET trial data. Model was calculate average life-years gained (LYG) costs post-progression mCRPC treatment. Simulation period 15 years one cycle 1 month. In “cost–effectiveness” analysis, we calculated addition, plus vs benchmark PREVAIL both cases, LYG over 15-year an efficacy criteria. To rate patients, potential number who could be treated 2021–2024 taken account. Results According model, 7.59 5.12 11,193,802 rubles per patient years, which 8,597,131 higher than when using (2,596,672 rubles). (vs 3,484,362 life-year gained. first line 5,899,418 combination Russia can started annually by 2,410 patients. If they all receive total 561 averted deaths among expected 2021–2024. Conclusion system, rubles. Enzalutamide make significant achieving target rates